Share this Page:
Tivozanib has been included as a first-line treatment recommendation for advanced renal cell carcinoma (aRCC) in new European Society of Medical Oncology (ESMO) clinical practice guidelines for RCC, published last month.
Tivozanib is recommended as a first-line treatment option for people with advanced clear cell RCC of good (favourable) risk or intermediate risk.
Tivozanib is a potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI). Tivozanib was granted a license by the European Commission (EC) in August 2017 for first-line treatment of aRCC, and was recommended for untreated adults with aRCC by NICE for England and Wales in March 2018, and the SMC for Scotland in July 2018.
Tivozanib was given marketing authorisation based on evidence from the phase 3 TiVO-1 clinical trial, which showed superior progression free survival and an improved side effect profile compared to sorafenib, another VEGFR-TKI.
Lee Morley, Chief Executive of EUSA Pharma, the manufacturers of tivozanib, said “I am pleased that the important European guidelines have been updated to include tivozanib as a recommendation for first line treatment for aRCC. With kidney cancer expected to be one of the fastest increasing cancers over the next ten years, we remain committed to ensuring the availability of tivozanib across the EU in line with the indication as a monotherapy in the first-line setting treatment of aRCC.”